Stockholders approve Amended 2014 Plan adding 4.75M shares; annual meeting results

Kura Oncology, Inc.

Stockholders approved Amended 2014 Equity Incentive Plan, increasing authorized shares by 4,750,000.
Elected Helen Collins, M.D., Thomas Malley, and Carol Schafer as Class II directors until 2028.
Ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2025.
Advisory vote on executive compensation approved with 63,155,796 for, 1,522,754 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.